Copyright
©The Author(s) 2020.
World J Hepatol. Nov 27, 2020; 12(11): 1046-1054
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1046
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1046
Table 2 Positive rates of alpha-fetoprotein and PIVKA-II in patients whose tumor size was ≤ 2 cm and those whose tumor size was more than 2 cm
| Maximum diameter of HCC nodules | P value1 | |||
| ≤ 2 cm, n = 394 | > 2 cm, n = 539 | |||
| AFP | (+) | 195 (49.5%) | 281 (52.1%) | 0.4254 |
| (-) | 199 (50.5%) | 258 (47.9%) | ||
| PIVKA | (+) | 123 (31.2%) | 385 (71.4%) | < 0.0001 |
| (-) | 271 (68.8%) | 154 (28.6%) | ||
- Citation: Tarao K, Nozaki A, Komatsu H, Komatsu T, Taguri M, Tanaka K, Chuma M, Numata K, Maeda S. Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases. World J Hepatol 2020; 12(11): 1046-1054
- URL: https://www.wjgnet.com/1948-5182/full/v12/i11/1046.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i11.1046